Identification of FDA‐approved drugs that increase mevalonate kinase in hyper IgD syndrome

Abstract

AbstractMevalonate kinase deficiency (MKD) is an autoinflammatory metabolic disorder caused by bi‐allelic loss‐of‐function variants in the MVK gene, resulting in decreased activity of the encoded mevalonate kinase (MK). Clinical presentation ranges from the severe early‐lethal mevalonic aciduria to the milder hyper‐IgD syndrome (MKD–HIDS), and is in the majority of patients associated with recurrent inflammatory episodes with often unclear cause. Previous studies with MKD–HIDS patient cells indicated that increased temperature, as caused by fever during an inflammatory episode, lowers the residual MK activity, which causes a temporary shortage of non‐sterol isoprenoids that promotes the further development of inflammation. Because an increase of the residual MK activity is expected to make MKD–HIDS patients less sensitive to developing inflammatory episodes, we established a cell‐based screen that can be used to identify compounds and/or therapeutic targets that promote this increase. Using a reporter HeLa cell line that stably expresses the most common MKD–HIDS variant, MK‐V377I, C‐terminally tagged with bioluminescent NanoLuc luciferase (nLuc), we screened the Prestwick Chemical Library®, which includes 1280 FDA‐approved compounds. Multiple compounds increased MK‐V377I‐nLuc bioluminescence, including steroids (i.e., glucocorticoids, estrogens, and progestogens), statins and antineoplastic drugs. The glucocorticoids increased MK‐V377I‐nLuc bioluminescence through glucocorticoid receptor signaling. Subsequent studies in MKD–HIDS patient cells showed that the potent glucocorticoid clobetasol propionate increases gene transcription of MVK and other genes regulated by the transcription factor sterol regulatory element‐binding protein 2 (SREBP‐2). Our results suggest that increasing the flux through the isoprenoid biosynthesis pathway by targeting the glucocorticoid receptor or SREBP‐2 could be a potential therapeutic strategy in MKD–HIDS.